NCCN Resource Helps Patients With Leukemia Understand Treatment Options

05/15/18

The National Comprehensive Cancer Network (NCCN) has released a free resource to help patients with acute myeloid leukemia (AML) and their families become better informed in treatment decision-making.

The manual—called “NCCN Guidelines for Patients: AML”—was funded and sponsored by the NCCN Foundation and Be The Match. It contains information from the NCCN Clinical Practice Guidelines in Oncology.

“AML, although a rare cancer, is the most common disease treated by allogeneic bone marrow transplant (BMT). Due to advances in treatment and supportive care, potentially curative therapies like BMT are more available to patients with AML,” said Elizabeth A Murphy, EdD, RN, vice president, Patient & Health Professional Services and Education & Training, Be The Match, in a press release (May 14, 2018). “The release of the new NCCN patient guidelines for AML will help patients and their families have access to easy-to-understand information so they can make informed decisions about their treatment.”

The NCCN Guidelines for Patients: AML is also endorsed by the Aplastic Anemia and MDS International Foundation, Blood & Marrow Transplant Information Network, Leukemia and Lymphoma Society, and National Bone Marrow Transplant Link. Each booklet contains a list of questions to ask doctors, patient-friendly illustrations, and a glossary of informative terms and acronyms. The booklets are available online at NCCN.org/patients.

-----

Related Content

Older AML Patients Experience High Cost Burdens

Prognostic, Treatment Perceptions Differ Between AML Patients, Oncologists

-----

“Treating AML can be very complex, and requires a team approach,” explained Margaret R O’Donnell, MD, City of Hope, and chair, NCCN Guidelines Panel for AML. “I am glad that patients everywhere now have a reliable source for free, evidence-based information that they can read and absorb at their own pace.”

In the coming months, the NCCN plans to release new Guidelines for Patients with Hepatobiliary, Bladder, and Uterine and Endometrial cancers.—Zachary Bessette